Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 1993 Mar;30(3):210–213. doi: 10.1136/jmg.30.3.210

Carrier detection of Hunter syndrome (MPS II) by biochemical and DNA techniques in families at risk.

W Schröder 1, L Petruschka 1, M Wehnert 1, M Zschiesche 1, G Seidlitz 1, J J Hopwood 1, F H Herrmann 1
PMCID: PMC1016301  PMID: 8097259

Abstract

DNA based and biochemical diagnosis of MPS II was performed on 13 unrelated families using Southern blotting. The 35S-sulphate accumulation in cultured fibroblasts was investigated and the iduronate-2-sulphatase (IDS) activity in the serum determined. Sixteen patients and 36 females at risk were screened for structural aberrations and by RFLP analysis using the intragenic probe pc2S15 and probes VK23B, VK21A, and II-10 for the flanking loci DXS297, DXS296, and DXS466. Structural alterations were found in the DNA of two patients. One of them showed a major deletion including the whole coding sequence of the IDS gene. An aberrant Southern fragment occurred in the HindIII/pc2S15 blot of the other patient suggesting a new HindIII restriction site by point mutation in an IDS gene intron. Twenty-nine females were confirmed as carriers, and for five women the heterozygous state could be excluded. Prenatal diagnosis can be offered to 27 women if requested.

Full text

PDF
210

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer I. M., Harper P. S., Wusteman F. S. An improved assay for iduronate 2-sulphate sulphatase in serum and its use in the detection of carriers of the Hunter syndrome. Clin Chim Acta. 1981 Apr 27;112(1):107–112. doi: 10.1016/0009-8981(81)90274-6. [DOI] [PubMed] [Google Scholar]
  2. Davies K. E., Speer A., Herrmann F., Spiegler A. W., McGlade S., Hofker M. H., Briand P., Hanke R., Schwartz M., Steinbicker V. Human X chromosome markers and Duchenne muscular dystrophy. Nucleic Acids Res. 1985 May 24;13(10):3419–3426. doi: 10.1093/nar/13.10.3419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Herrmann F. H., Wulff K., Schütz M., Wehnert M. Deletion screening and prenatal diagnosis of Duchenne muscular dystrophy using cDNA probes Cf 23a and Cf 56a. Eur J Pediatr. 1990 Jan;149(4):263–265. doi: 10.1007/BF02106289. [DOI] [PubMed] [Google Scholar]
  4. Hulsebos T. J., Oostra B. A., Broersen S., Smits A., van Oost B. A., Westerveld A. New distal marker closely linked to the fragile X locus. Hum Genet. 1991 Jul;87(3):369–372. doi: 10.1007/BF00200922. [DOI] [PubMed] [Google Scholar]
  5. Machill G., Barbujani G., Danieli G. A., Herrmann F. H. Segregation and sporadic cases in families with Hunter's syndrome. J Med Genet. 1991 Jun;28(6):398–401. doi: 10.1136/jmg.28.6.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Petruschka L., Machill G., Wehnert M., Seidlitz G., Knapp A. Reliability of the Tønnesen technique for the identification of Hunter carriers. Hum Genet. 1983;64(4):404–406. doi: 10.1007/BF00292377. [DOI] [PubMed] [Google Scholar]
  7. Southern E. M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol. 1975 Nov 5;98(3):503–517. doi: 10.1016/s0022-2836(75)80083-0. [DOI] [PubMed] [Google Scholar]
  8. Suthers G. K., Mulley J. C., Voelckel M. A., Dahl N., Väisänen M. L., Steinbach P., Glass I. A., Schwartz C. E., van Oost B. A., Thibodeau S. N. Genetic mapping of new DNA probes at Xq27 defines a strategy for DNA studies in the fragile X syndrome. Am J Hum Genet. 1991 Mar;48(3):460–467. [PMC free article] [PubMed] [Google Scholar]
  9. Suthers G. K., Oberlé I., Nancarrow J., Mulley J. C., Hyland V. J., Wilson P. J., McCure J., Morris C. P., Hopwood J. J., Mandel J. L. Genetic mapping of new RFLPs at Xq27-q28. Genomics. 1991 Jan;9(1):37–43. doi: 10.1016/0888-7543(91)90218-4. [DOI] [PubMed] [Google Scholar]
  10. Tønnesen T., Lykkelund C., Güttler F. Diagnosis of Hunter's syndrome carriers; radioactive sulphate incorporation into fibroblasts in the presence or fructose 1-phosphate. Hum Genet. 1982;60(2):167–171. doi: 10.1007/BF00569706. [DOI] [PubMed] [Google Scholar]
  11. Tønnesen T. The use of fructose 1-phosphate to detect Hunter heterozygotes in fibroblast cultures from high-risk carriers. Hum Genet. 1984;66(2-3):212–216. doi: 10.1007/BF00286603. [DOI] [PubMed] [Google Scholar]
  12. Wehnert M., Hopwood J. J., Schröder W., Herrmann F. H. Structural gene aberrations in mucopolysaccharidosis II (Hunter). Hum Genet. 1992 Jun;89(4):430–432. doi: 10.1007/BF00194316. [DOI] [PubMed] [Google Scholar]
  13. Wilson P. J., Morris C. P., Anson D. S., Occhiodoro T., Bielicki J., Clements P. R., Hopwood J. J. Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc Natl Acad Sci U S A. 1990 Nov;87(21):8531–8535. doi: 10.1073/pnas.87.21.8531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Yu S., Suthers G. K., Mulley J. C. A BclI RFLP for DXS296 (VK21) near the fragile X. Nucleic Acids Res. 1990 Feb 11;18(3):690–690. doi: 10.1093/nar/18.3.690-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Zlotogora J., Bach G. Heterozygote detection in Hunter syndrome. Am J Med Genet. 1984 Mar;17(3):661–665. doi: 10.1002/ajmg.1320170317. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES